Exploring the Benefit of 2-Methylbutyric Acid in Patients Undergoing Hemodialysis Using a Cardiovascular Proteomics Approach
Open Access
- 12 December 2019
- Vol. 11 (12) , 3033
Abstract
Short-chain fatty acids (SCFAs) can reduce pro-inflammatory parameters and oxidative stress, providing potential cardiovascular (CV) benefits. Although some evidence links SCFAs with host metabolic health via several biological mechanisms, the role of SCFA on CV disease in patients with kidney disease remains unclear. Herein, we investigate the association between a SCFA, 2-methylbutyric acid, and target CV proteomics to explore the potential pathophysiology of SCFA-related CV benefit in patients with kidney disease. Circulating 2-methylbutyric acid was quantified by high-performance liquid chromatography and 181 CV proteins by a proximity extension assay in 163 patients undergoing hemodialysis (HD). The associations between 2-methylbutyric acid and CV proteins were evaluated using linear regression analysis with age and gender, and multiple testing adjustment. The selected CV protein in the discovery phase was further confirmed in multivariable-adjusted models and evaluated by continuous scale association. The mean value of circulating 2-methylbutyric acid was 0.22 ± 0.02 µM, which was negatively associated with bone morphogenetic protein 6 (BMP-6) according to the false discovery rate (FDR) multiple testing adjustment method. The 2-methylbutyric acid level remained negatively associated with BMP-6 (β coefficient −1.00, 95% confidence interval −1.45 to −0.55, p < 0.001) after controlling for other CV risk factors in multivariable models. The cubic spline curve demonstrated a linear relationship. In conclusion, circulating 2-methylbutyric acid level was negatively associated with BMP-6, suggesting that this pathway maybe involved in vascular health in patients undergoing HD. However, further in vitro work is still needed to validate the translation of the mechanistic pathways.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 105-2628-B-037-005-MY2, MOST 106-2113-M-002 -013-MY2, MOST 107-2314-B-037-104, MOST 107-2314-B-037-098-MY3)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH105-5R15, KMUH106-6R17, KMUH107-7R16, KMUH107-7R78)
- Kaohsiung Medical University (KMUH106-6T03, KMUH106-6T07, KMU-Q108024, KMU-Q108027)
This publication has 55 references indexed in Scilit:
- Gut Microbial Product Predicts Cardiovascular Risk in Chronic Kidney Disease PatientsAmerican Journal of Nephrology, 2018
- Supplementation of Short-Chain Fatty Acid, Sodium Propionate, in Patients on Maintenance Hemodialysis: Beneficial Effects on Inflammatory Parameters and Gut-Derived Uremic Toxins, A Pilot Study (PLAN Study)Journal of Clinical Medicine, 2018
- Short-chain Fatty Acids: A Link Between Prebiotics And Microbiota In Chronic Kidney DiseaseFuture Microbiology, 2017
- Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney DiseaseJournal of the American Heart Association, 2017
- Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the hostCurrent Opinion in Pharmacology, 2013
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and preventionThe Lancet, 2013
- Chronic kidney disease: global dimension and perspectivesThe Lancet, 2013
- Chronic Kidney Disease as a Coronary Artery Disease Risk EquivalentCurrent Cardiology Reports, 2013
- Regulation of short-chain fatty acid productionProceedings of the Nutrition Society, 2003
- Short-Chain Fatty Acids and Human Colonic Function: Roles of Resistant Starch and Nonstarch PolysaccharidesPhysiological Reviews, 2001